Moreover, the co-administration of a selective NOD1 agonist attenuated the anti-inflammatory effects of Avn-C, suggesting that Avn-C may exert its protective role, at least in part, through the modulation of NOD1/RIP2/NF-κB signaling in the context of HFD-induced AD pathology. Here, RIPK2 is linked to Alzheimer disease.